Format

Send to

Choose Destination
Circ Res. 2018 Apr 27;122(9):1238-1258. doi: 10.1161/CIRCRESAHA.117.311002.

Cardiovascular Metabolomics.

McGarrah RW1,2,3, Crown SB1, Zhang GF1,4,3, Shah SH1,2,3, Newgard CB5,4,3,6.

Author information

1
From the Sarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute (R.W.M., S.B.C., G.F.Z., S.H.S., C.B.N.).
2
Division of Cardiology (R.W.M., S.H.S.).
3
Department of Medicine (R.W.M., G.F.Z., S.H.S., C.B.N.).
4
Division of Endocrinology (G.F.Z., C.B.N.).
5
From the Sarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute (R.W.M., S.B.C., G.F.Z., S.H.S., C.B.N.) chris.newgard@duke.edu.
6
Departments of Pharmacology and Cancer Biology (C.B.N.), Duke University Medical Center, Durham, NC.

Abstract

Disturbances in cardiac metabolism underlie most cardiovascular diseases. Metabolomics, one of the newer omics technologies, has emerged as a powerful tool for defining changes in both global and cardiac-specific metabolism that occur across a spectrum of cardiovascular disease states. Findings from metabolomics studies have contributed to better understanding of the metabolic changes that occur in heart failure and ischemic heart disease and have identified new cardiovascular disease biomarkers. As technologies advance, the metabolomics field continues to evolve rapidly. In this review, we will discuss the current state of metabolomics technologies, including consideration of various metabolomics platforms and elements of study design; the emerging utility of stable isotopes for metabolic flux studies; and the use of metabolomics to better understand specific cardiovascular diseases, with an emphasis on recent advances in the field.

KEYWORDS:

amino acids; cardiovascular diseases; heart failure; ketone bodies; metabolism

PMID:
29700070
PMCID:
PMC6029726
[Available on 2019-04-27]
DOI:
10.1161/CIRCRESAHA.117.311002

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center